Cerenion and the Hospital District of Southwest Finland have signed a collaboration agreement for a research project investigating the application of C-Trend® to patients with acute ischemic stroke. In the project, led by the Turku University Hospital (TYKS), the possibility to use C-Trend® for continuous evaluation of the effect of recanalization therapy and evolution and possible complications of stroke after the treatment is studied.
Stroke is a condition in which blood supply to part of the brain is cut off typically due to a clot or rupture of a vessel. It is one of the leading causes of death and disability globally. Treatment in the acute phase aims at quick recanalization meaning returning normal blood flow to the brain. Thrombectomy, a procedure in which the clot is removed mechanically, is today a standard procedure in the treatment of large vessel occlusion (LVO) strokes together with drug-based thrombolytic therapy. EEG offers a promising bedside method to monitor the brain function of stroke patients supplementing the information provided by clinical examination and imaging. Its use, however, has been limited by the lack of suitable EEG devices and analysis tools for interpreting the recordings required by the demanding treatment environment.
In the upcoming study, patients suffering from LVO are monitored with a BrainStatus EEG device continuously throughout their acute treatment phase. C-Trend® software is used to evaluate the changes in the EEG at the emergency, during the thrombectomy, and in the stroke unit after the treatment. The study aims at investigating whether C-Trend® provides beneficial information related to the severity of the stroke and success in the treatment and if the technology offers potential to be used as a part of the acute treatment of stroke patients. The study is supervised by Associate Professor Jori Ruuskanen, MD-PhD from TYKS Neurocenter.